Ischemia - Pipeline Review, H2 2015 Now Available at iData Insights Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia - Pipeline Review, H2 2015, provides an overview of the Ischemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Ischemia Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 1
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemiapipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173358/ischemia-pipeline-review-h2-2015 Table of Contents
Introduction 8 Global Markets Direct Report Coverage 8 Ischemia Overview 9 Therapeutics Development 10 Pipeline Products for Ischemia - Overview 10 Pipeline Products for Ischemia - Comparative Analysis 11 Ischemia - Therapeutics under Development by Companies 12 Ischemia - Therapeutics under Investigation by Universities/Institutes 16 Ischemia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Ischemia - Products under Development by Companies 20 Ischemia - Products under Investigation by Universities/Institutes 24 Ischemia - Companies Involved in Therapeutics Development 25 Alize Pharma SAS 25 Amyndas Pharmaceuticals LLC 26 AnGes MG, Inc. 27 Apceth GmbH & Co. KG 28 Athersys, Inc. 29 2
Baxalta Incorporated 30 Caladrius Biosciences, Inc. 31 Cellmid Limited 32 CoDa Therapeutics, Inc. 33 CohBar, Inc. 34 Cynata Therapeutics Limited 35 DNAVEC Corporation 36 GlaxoSmithKline Plc 37 Hemostemix Ltd 38 IntelliCell BioSciences Inc. 39 Juventas Therapeutics, Inc. 40 Kasiak Research Private Limited 41 Lixte Biotechnology Holdings, Inc. 42 Mesoblast Limited 43 Miltenyi Biotec GmbH 44 Mirrx Therapeutics A/S 45 Multi Gene Vascular Systems Ltd 46 NoNO, Inc. 47 Nyken BV 48 Pathfinder Cell Therapy, Inc. 49 Pharmicell Co., Ltd. 50 Pluristem Therapeutics Inc. 51 Protagenic Therapeutics Inc. 52
3
ReNeuron Group Plc 53 Sihuan Pharmaceutical Holdings Group Ltd. 54 Stempeutics Research Private Limited 55 Targazyme, Inc. 56 Taxus Cardium Pharmaceuticals Group Inc. 57 TikoMed AB 58 U.S. Stem Cell, Inc. 59 Vericel Corporation 60 ViroMed Co., Ltd. 61 Ischemia - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 68 Assessment by Molecule Type 70 Drug Profiles 72 AB-002 - Drug Profile 72 ACP-01 - Drug Profile 74 AdipoCell - Drug Profile 76 Alda-1 - Drug Profile 78 Alecmestencel-T - Drug Profile 79 alferminogene tadenovec - Drug Profile 80 AntimiR-199a - Drug Profile 82 ASCT-01 - Drug Profile 83 4
Autologous Vascular Cells Therapy - Drug Profile 84 AZP-531 - Drug Profile 85 beperminogene perplasmid - Drug Profile 87 bucillamine - Drug Profile 92 CD-52 - Drug Profile 93 Cell Therapy for Critical Limb Ischemia - Drug Profile 94 Cell Therapy for Ischemia - Drug Profile 95 Cell Therapy for Ischemia - Drug Profile 96 Cellgram for Severe Lower Limb Ischemia - Drug Profile 97 Cinepazide Mesylate - Drug Profile 98 CLBS-12 - Drug Profile 99 CMK-103 - Drug Profile 100 daprodustat - Drug Profile 101 DVC1-0101 - Drug Profile 103 EP-80317 - Drug Profile 105 Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 106 Humanin - Drug Profile 107 ixmyelocel-T - Drug Profile 109 JVS-100 - Drug Profile 112 JVS-200 - Drug Profile 114 LB-100 - Drug Profile 115 LB-102 - Drug Profile 117 MicroRNA for Ischemia - Drug Profile 119
5
MPC-25IC - Drug Profile 120 MultiGeneAngio - Drug Profile 121 MultiStem - Drug Profile 123 NYK-1112 - Drug Profile 127 Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile 128 Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile 129 Pathfinder Cells - Drug Profile 130 Peptagon - Drug Profile 132 PLX-PAD - Drug Profile 133 PMC-6 - Drug Profile 137 Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 138 PT-00114 - Drug Profile 139 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 140 Recombinant Protein for Critical Limb Ischemia - Drug Profile 141 Recombinant Protein for Ischemia - Drug Profile 142 Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 143 Refacell-CLI - Drug Profile 144 Rejuveinix - Drug Profile 145 ReN-009 - Drug Profile 146 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 147 Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 148 Small Molecules for Renal Failure and Renal Ischemia - Drug Profile 149 Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 150 6
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 151 Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 152 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 153 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 154 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 156 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 158 Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 159 Stempeucel - Drug Profile 160 Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 163 TM-700 - Drug Profile 164 TZ-101 - Drug Profile 165 VM-202 - Drug Profile 167 Ischemia - Recent Pipeline Updates 169 Ischemia - Dormant Projects 206 Ischemia - Discontinued Products 212 Ischemia - Product Development Milestones 213 Featured News & Press Releases 213 Appendix 218 Methodology 218 Coverage 218 Secondary Research 218 Primary Research 218 Expert Panel Validation 218
7
Contact Us 218 Disclaimer 219"
Read More http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemia-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8